Amifostine

CHEMBL1006 Phase 4 ได้รับการอนุมัติ Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
214.2 g/mol
LogP
-4.5
Phase
4

A cytoprotective prodrug that is converted to an active metabolite in normal tissues to scavenge free radicals and reduce the toxicity of radiation and certain chemotherapy drugs like cisplatin, protecting healthy cells while having limited activity in tumor tissue. It is used to reduce kidney toxicity from cisplatin and decrease dry mouth from head and neck radiation therapy.

น้ำหนักโมเลกุล

214.2300 g/mol

LogP

-4.50

TPSA

121.00 Ų

Lipinski RO5

ผ่าน

ด้านการรักษา

กลไกการออกฤทธิ์

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

กลไก

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

โครงสร้าง 2 มิติ

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

NCCCNCCSP(=O)(O)O

InChI

InChI=1S/C5H15N2O3PS/c6-2-1-3-7-4-5-12-11(8,9)10/h7H,1-6H2,(H2,8,9,10)

Molecular Formula

C5H15N2O3PS

HBD / HBA

4 / 6

พันธะที่หมุนได้

7

อะตอมหนัก

12

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

คำถามที่พบบ่อย

A cytoprotective prodrug that is converted to an active metabolite in normal tissues to scavenge free radicals and reduce the toxicity of radiation and certain chemotherapy drugs like cisplatin, protecting healthy cells while having limited activity in tumor tissue. It is used to reduce kidney toxicity from cisplatin and decrease dry mouth from head and neck radiation therapy.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Amifostine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1006. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 2141. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

ข้อจำกัดความรับผิดชอบทางการแพทย์

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.